Biotech News

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Akebia Therapeutics (AKBA)Akebia TherapeuticsConference / presentation

Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST.

A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.

The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com , which does not form a part of this release.

Akebia Therapeutics Contact Mercedes Carrasco [email protected]

Related news

Akebia Therapeutics

Kidney-Disease Company Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders. Vafseo Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults...

Recent company news

Stock data

Close
0.91 USD
Market cap
251.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States